MA45685A - Formes cristallines de 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide - Google Patents

Formes cristallines de 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide

Info

Publication number
MA45685A
MA45685A MA045685A MA45685A MA45685A MA 45685 A MA45685 A MA 45685A MA 045685 A MA045685 A MA 045685A MA 45685 A MA45685 A MA 45685A MA 45685 A MA45685 A MA 45685A
Authority
MA
Morocco
Prior art keywords
tetramethyltetrahydro
dimethylcyclohex
pyran
carboxamide
pyridin
Prior art date
Application number
MA045685A
Other languages
English (en)
Inventor
David Breslin
Nagy E Fawzy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA45685A publication Critical patent/MA45685A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Pyrane Compounds (AREA)
MA045685A 2016-07-18 2017-07-17 Formes cristallines de 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide MA45685A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662363622P 2016-07-18 2016-07-18

Publications (1)

Publication Number Publication Date
MA45685A true MA45685A (fr) 2019-05-22

Family

ID=59631847

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045685A MA45685A (fr) 2016-07-18 2017-07-17 Formes cristallines de 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide

Country Status (16)

Country Link
US (1) US10314821B2 (fr)
EP (1) EP3484872B1 (fr)
JP (1) JP2019521159A (fr)
KR (1) KR20190026910A (fr)
CN (1) CN109952296A (fr)
AR (1) AR109079A1 (fr)
AU (1) AU2017299506B2 (fr)
BR (1) BR112019000982A2 (fr)
CA (1) CA3031230A1 (fr)
EA (1) EA201990320A1 (fr)
ES (1) ES2935647T3 (fr)
MA (1) MA45685A (fr)
MX (2) MX384614B (fr)
TW (1) TWI752980B (fr)
UY (1) UY37338A (fr)
WO (1) WO2018017444A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022094077A1 (fr) * 2020-10-30 2022-05-05 Athenex R&D, Llc Polymorphismes de mésylate hm30181

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2009058968A2 (fr) * 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarqueur utilisé pour évaluer une réponse à un traitement de fms
ES2658773T3 (es) 2012-08-07 2018-03-12 Janssen Pharmaceutica N.V. Procedimiento de sulfonilación usando fluoruro de nonafluorobutanosulfonilo
MX2015012344A (es) * 2013-03-15 2016-06-02 Janssen Pharmaceutica Nv 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrameti ltetrahidro-2h-piran-4-il)piridin-3-il)-1h-imidazol-2-carboxamida para el tratamiento de linfona de hodgkin.
WO2014151258A1 (fr) * 2013-03-15 2014-09-25 Janssen Pharmaceutica Nv Dérivés de pyridine substitués utiles en tant qu'inhibiteurs de kinase c-fms

Also Published As

Publication number Publication date
KR20190026910A (ko) 2019-03-13
TWI752980B (zh) 2022-01-21
UY37338A (es) 2018-01-31
WO2018017444A1 (fr) 2018-01-25
US10314821B2 (en) 2019-06-11
US20180133197A1 (en) 2018-05-17
JP2019521159A (ja) 2019-07-25
CA3031230A1 (fr) 2018-01-25
MX2019000749A (es) 2019-08-29
ES2935647T3 (es) 2023-03-08
EP3484872A1 (fr) 2019-05-22
EA201990320A1 (ru) 2019-06-28
MX2021006739A (es) 2021-07-15
MX384614B (es) 2025-03-14
CN109952296A (zh) 2019-06-28
AU2017299506B2 (en) 2021-08-05
EP3484872B1 (fr) 2022-11-30
TW201808941A (zh) 2018-03-16
AR109079A1 (es) 2018-10-24
AU2017299506A1 (en) 2019-02-07
BR112019000982A2 (pt) 2019-05-14

Similar Documents

Publication Publication Date Title
IL257124B (en) 2-(Het)aryl-converted compressed heterocyclic compounds as pest control agents
ZA201802797B (en) 2-(het)aryl-substituted condensed bicyclic heterocyclic derivatives as pest control agents
PT3687999T (pt) Derivados de rapamicina
LT3523301T (lt) Pakeistieji pirazolo[1,5-a]piridino junginiai kaip ret kinazės slopikliai
LT3269370T (lt) Naujas kondensuotas pirimidino junginys arba jo druska
DK3436444T3 (da) Heterocyklisk forbindelse
DK3498693T3 (da) Heterocyklisk forbindelse
BR112017027339A2 (pt) derivados de piperidina 1,4-substituída
IL247833A0 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA46972A (fr) Forme polymorphe de sépiaptérine
IL265166B (en) Anti-influenza virus pyrimidine derivatives
EP3828174A4 (fr) Dérivé de pyridazinone
IL260908B (en) Substituted 2-(het)aryl-imidazolyl-carboxyamides as pest control agents
LT3160958T (lt) (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizochinolin-2(1h)-yl)-2-hidroksipropil)pirimidin-4-karboksamido kristalinės druskos
EP3376865A4 (fr) 4-((6-(2,4-difluorophényl)-1,1-difluoro-2-hydroxy-3-(1h
DK3642210T3 (da) Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
EP3564216A4 (fr) Dérivé pyrimidine
DK3390407T3 (da) Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
EP3283171A4 (fr) Dérivés d'amphotéricine b
PT3625224T (pt) Derivados de indol n-substituídos
DK3450436T3 (da) Kondenseret heterocyklisk forbindelse
EP3333163A4 (fr) Dérivé de guanidine substitué
MA46567A (fr) Formes cristallines de l'éravacycline
MA47129A (fr) Sel de composé pipéridine substitué